Developer docs
API playgroundTry for free, no card

Search company profiles

PHASE II International

Full company profile

uuid002eff9

Namestring
PHASE II International
Legal namestring
PHASE II International Limited
Websiteurl
phase-ii.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

PHASE II International is a privately held life science consultancy, founded in 1997 and incorporated in England and Wales, that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies. The firm operates through a curated 'Network of Excellence' model — a global roster of independent specialists in medical strategy, health economics, epidemiology, scientific writing, design, and AI — assembled bespoke for each client engagement under the personal oversight of its Executive Directors. Two engagement models structure delivery: Agency of Record (multi-year integrated strategic support) and Ad Hoc Consultancy (project-specific expertise, frequently for early-stage pipeline products).

The company sells three integrated service pillars: Market Intelligence Services (MLA, CBA, CPA, MM&F, CIS, KOL mapping); Strategy Development (eleven proprietary moderated workshop processes including Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, BrandPlan, PatPlan); and Communication Programs (branded/unbranded creative campaigns, scientific congress booth development, video). A branded 'PHASE II | AI' practice overlays the core offering with NLP, machine learning predictive analytics (via partnership with PredictaMed for sub-clinical disease detection), and generative AI creative ideation. The customer base spans hematology, oncology, immunology, and rare disease, with named clients including BeOne, Almirall, Curis Pharma, and Pharvaris. A separate sister organization, Scientific Education Support (SES), delivers independent accredited medical education and is fully firewalled from the consultancy.

Short descriptiontext

PHASE II International is a privately held, London-based life science consultancy founded in 1997 that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies through a curated Network of Excellence model and an AI-powered practice area.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science consultancy, pharmaceutical market intelligence, biopharmaceutical strategy, medical communications agency, healthcare brand strategy
Industry2 codes
PRIMARYHLAIALAJ
Post-Approval Clinical Development (Phase IV & Lifecycle Management)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Life Science Consultancy
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Market Intelligence Services
TypeProfessional Services
Description

MLA (Market Landscape Analysis), CBA (Competitor Benchmarking Analysis), CPA (Customer Profiling Analysis), MM&F (Market Modelling & Forecasting), CIS (Competitor Intelligence Services), BIR (Bespoke Insight Research), KOL Identification & Influence Mapping

phase-ii.com
2Strategy Development Services
TypeProfessional Services
Description

Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, Thought leader advocacy planning, BrandPlan, PatPlan processes delivered through moderated workshops

phase-ii.com
3Communication Programs
TypeProfessional Services
Description

Integrated Communications & Commercialization Planning, Project Implementation, Creative Advertising Campaigns (branded and unbranded), Scientific exhibition booth panels, Video production

phase-ii.com
4Agency of Record Engagements
TypeManaged Services
Description

Full array of integrated strategic services encompassing market research, analysis and intelligence services; strategic product and launch planning; and development/implementation of scientific, market access and creative medical communication programs

phase-ii.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Custom Professional Services
ModelOtherBilling cadenceMulti-year contract
Notes

Services delivered through Agency of Record engagements or ad hoc consultancy assignments. No standardized pricing tiers publicly listed.

phase-ii.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PHASE II International is a life science consultancy that helps biopharmaceutical companies plan, launch and lifecycle-manage products by delivering market intelligence, strategic planning and medical communications through a curated Network of Excellence of independent specialists. It bundles these capabilities into ongoing Agency of Record engagements and project-based Ad Hoc Consultancy assignments, with an embedded "PHASE II | AI" practice applying NLP, machine learning predictive analytics for early disease detection, and generative AI tools to its intelligence, strategy and creative workstreams.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Supported over 30 life science companies and 35 life science brands since 1997
+2 more records
Product overview1 text field

PHASE II International is a life science consultancy operating since 1997 through a curated 'Network of Excellence' — a virtual organization of independent specialists assembled bespoke for each client engagement. The company offers three integrated core service pillars: Market Intelligence Services (MLA, CBA, CPA, MM&F, CIS, BIR, KOL Identification), Strategy Development (Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, BrandPlan, PatPlan), and Communication Programs (integrated communications and branded/unbranded creative advertising campaigns). These services are delivered across two engagement models — Agency of Record (ongoing strategic support) and Ad Hoc Consultancy (project-specific expertise) — primarily supporting biopharmaceutical companies in pre-launch, launch, and lifecycle phases across hematology, oncology, immunology, and rare disease. A distinct AI-powered practice area branded 'PHASE II | AI' overlays the core services with NLP for market research, machine learning predictive analytics for early disease detection and clinical trial patient matching, and generative AI tools for creative ideation. The company also maintains sister organization Scientific Education Support (SES) for independent accredited medical education, which is operationally firewalled from PHASE II.

Product and service9 records
1Market Intelligence Services
CategoryMarket Intelligence / Market Research
Description

A suite of market research and intelligence offerings for life science companies encompassing Market Landscape Analysis (MLA), Competitor Benchmarking Analysis (CBA), Customer Profiling Analysis (CPA), Market Modelling & Forecasting (MM&F), Competitor Intelligence Services (CIS), Bespoke Insight Research (BIR), and KOL Identification & Influence Mapping. Designed for Business Intelligence, Medical Affairs and Commercial teams seeking market intelligence, competitor benchmarking and strategic insights to support pre-launch and launch decisions.

2Strategy Development
CategoryStrategic Consulting
Description

A portfolio of proprietary strategic planning processes delivered through moderated workshops: Pre-Strat (Pre-Clinical Candidate Selection), TPPO (Target Product Profile Optimization), TCPO (Target Clinical Profile Optimization), SciPlat (Scientific Platform & Core Claims), PosStrat (Product Positioning & Key Messages), ComStrat (Communications Strategy), ComPlan (Communication Planning), SciPlan (Scientific Publication Planning), MarPlan (Market Access Planning), Thought Leader Advocacy Planning, BrandPlan (Brand Communications Planning), and PatPlan (Patient Engagement & Advocacy Planning). For Medical Affairs, Clinical Development, Market Access and Commercial teams planning new product launches and lifecycle phases.

3Communication Programs
CategoryMedical Communications
Description

Integrated communications and creative advertising campaigns (branded and unbranded) that translate complex scientific and technical information into clear, actionable messaging for healthcare professionals, patients, payers and the general public. Includes scientific exhibition booth panel development, video production and full project implementation. For Commercial and Marketing teams within biopharmaceutical companies.

4PHASE II | AI
CategoryAI-Enabled Consulting Capability
Description

AI-powered practice area encompassing Natural Language Processing (NLP) for market research transcription, sentiment analysis (emotion detection) and report generation; machine learning algorithms and AI-powered analytics platforms for predictive analytics, early disease detection (up to five years pre-onset) and matching patients to open/recruiting clinical trials based on eligibility criteria; and generative creative design tools (DALL-E, GPT-3) for medical education and marketing communication ideation.

5Market Access & HEOR Services
CategoryMarket Access & Health Economics
Description

Market access strategies, optimized health economics outcomes research programs, and value demonstration communications for biopharmaceutical clients. Encompasses Systematic Literature Reviews (SLRs), Global Value Dossiers (GVDs), HTA submissions and implementation per EU country, and pathways to successful negotiation with local payers across EU countries. For Market Access teams seeking to demonstrate clinical and economic value of products.

6Strategic Advisory Board Services
CategoryStrategic Advisory / KOL Engagement
Description

PHASE II-moderated Expert Advisory Boards covering global regions (US, Europe, Asia Pacific) supporting Phase 2-to-Phase 3 transition planning. Includes facilitation of consensus disease definitions, unmet clinical needs, target patient segmentation, TPP criteria, AI prediction models for disease identification, and inclusion/exclusion criteria for Phase 3 trials.

7Scientific Exhibition Booth Panel Development
CategoryCongress / Event Scientific Content
Description

Full-service scientific exhibition booth panel development for international congresses (EHA, ASCO, ASH), encompassing research, copywriting, editing, referencing, original graphics creation using BioRender, high-resolution artwork preparation, and logistics management for delivery to congress venues. For biopharmaceutical companies seeking scientific presence at major international hematology and oncology congresses.

8Corporate Brand Communications Guide
CategoryCorporate Branding
Description

Comprehensive corporate brand identity development and documentation services for pharmaceutical and biotechnology companies, including logo usage guidelines, vision line application, typography standards, color palettes, imagery guidelines, advertising templates, presentation templates, scientific poster templates, corporate brochure templates, and style guidelines for devices and icons.

9Clinical Trial Center Mapping & Profiling
CategoryClinical Trial Intelligence / Site Mapping
Description

Market intelligence service mapping and profiling clinical trial centers of excellence, including hospital type classification, hematology specialty, principal investigator details, patient volumes, Phase 1 facilities, and clinical trial participation status for both sponsor and competitor trials. For Clinical Development and Clinical Operations teams at biopharmaceutical sponsors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Network of Excellence (Associates & Partners)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on1997-01-01
Description

Since 1997, PHASE II has developed an extensive global Network of Excellence consisting of scientific and clinical thought leaders, discipline experts and associates as well as life science and academic partners. Key named partners include: Stephen Nicholson PhD (Medical Oncologist), Tim Hardman PhD (Senior Medical Strategist), Paul Miller PhD (Independent Health Economist), Melanie Martin MRPharmS (Director, A-Z Medical Writing), Susanne Gulliver BA MPH (Senior Epidemiologist), Felix Chapovsky MD (Medical Strategy Consultant), David Zsaritsky (President of The Agency Network, MJH Lifesciences), and many others across medical, creative, digital, health economics, market research, video production, and AI disciplines.

phase-ii.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

David Zsaritsky serves as President of The Agency Network (TAN), part of MJH Lifesciences, acting as US Partner Agency to PHASE II International. This partnership extends PHASE II's reach into the US market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Patient networks and associations PHASE II has collaborated with include: ALAN, Cancer Care, FOCiS, and Lymphoma Coalition. These partnerships support patient engagement and advocacy planning services.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Medical societies PHASE II has collaborated with include ELI, ELN, ESH, and FoCiS. These partnerships support scientific engagement and thought leader activities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

SES is PHASE II's sister organization specializing in independent and accredited medical education programs. Operations are completely firewalled from PHASE II. SES and PHASE II are separate legal entities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Tim Hardman PhD, Managing Director of Niche Science & Technology Ltd, serves as Senior Scientific Strategist and Medical Writer. Represents strategic partnership for scientific writing capabilities.

7NewLab Clinical Research
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Susanne Gulliver BA MPH, Senior Epidemiologist, Research & Operations and CEO of NewLab Clinical Research. Represents strategic partnership for epidemiological research capabilities.

phase-ii.com
8Miller Economics Ltd
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Paul Miller BA, MSc, PhD, Director at Miller Economics Ltd, serves as Value Demonstration/Health Economics Lead. Represents strategic partnership for health economics capabilities.

phase-ii.com
9Lessis Moore
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Maria Szmit, Director at Lessis Moore, provides Senior Graphic Design & UX capabilities. Represents strategic partnership for design services.

phase-ii.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare communications and consulting agency serving pharma and biotech with strategic planning and creative services. Comparable on launch strategy, KOL engagement and content development for life science clients.

TypeDirect peer
Description

Strategic consulting firm providing commercial strategy, market intelligence, and launch planning to biopharma clients. Directly comparable to PHASE II on the Strategy Development and Market Intelligence pillars of the offering.

TypeBroad incumbent
Description

Healthcare-focused marketing, communications and data analytics firm offering integrated commercial services to life science clients. Wider portfolio with data and technology capabilities beyond PHASE II's specialist footprint.

TypeDirect peer
Description

Strategic consultancy supporting pharma and biotech with medical affairs, market access and patient engagement consulting. Comparable to PHASE II's strategic advisory and HEOR-related service lines.

TypeDirect peer
Description

Medical communications agency offering scientific engagement, publications planning and strategic services to biopharma. Directly comparable across PHASE II's medical affairs, publications and stakeholder engagement services.

TypeDirect peer
Description

Specialist medical communications and consulting group with global delivery across commercial, medical and patient engagement functions. Competes head-to-head on lifecycle and launch services for life science brands.

TypeDirect peer
Description

Medical communications and consulting agency serving pharma and biotech across launch and lifecycle. Closely aligned to PHASE II's medical affairs, market access and brand communications workstreams.

TypeDirect peer
Description

Boutique medical communications agency focused on scientific storytelling and engagement for pharma clients. Overlaps with PHASE II's branded and unbranded creative, congress and advisory board support.

TypeBroad incumbent
Description

Global life science services company providing commercial and clinical solutions including market intelligence, launch support and consulting. Competes on the data depth and global delivery scale that PHASE II lacks.

TypeEmerging player
Description

Health communications agency with strong focus on rare disease and specialty therapeutics. Directly overlaps with PHASE II's rare disease launch work such as the Pharvaris HAE franchise.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PHASE II International

Life Science Consultancyphase-ii.com

PHASE II International is a privately held, London-based life science consultancy founded in 1997 that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies through a curated Network of Excellence model and an AI-powered practice area.

What PHASE II International does

PHASE II International is a privately held life science consultancy, founded in 1997 and incorporated in England and Wales, that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies. The firm operates through a curated 'Network of Excellence' model — a global roster of independent specialists in medical strategy, health economics, epidemiology, scientific writing, design, and AI — assembled bespoke for each client engagement under the personal oversight of its Executive Directors. Two engagement models structure delivery: Agency of Record (multi-year integrated strategic support) and Ad Hoc Consultancy (project-specific expertise, frequently for early-stage pipeline products).

The company sells three integrated service pillars: Market Intelligence Services (MLA, CBA, CPA, MM&F, CIS, KOL mapping); Strategy Development (eleven proprietary moderated workshop processes including Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, BrandPlan, PatPlan); and Communication Programs (branded/unbranded creative campaigns, scientific congress booth development, video). A branded 'PHASE II | AI' practice overlays the core offering with NLP, machine learning predictive analytics (via partnership with PredictaMed for sub-clinical disease detection), and generative AI creative ideation. The customer base spans hematology, oncology, immunology, and rare disease, with named clients including BeOne, Almirall, Curis Pharma, and Pharvaris. A separate sister organization, Scientific Education Support (SES), delivers independent accredited medical education and is fully firewalled from the consultancy.

PHASE II International firmographics

Firmographics
Name
PHASE II International
Legal name
PHASE II International Limited
Website
https://phase-ii.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
PHASE II International is a privately held, London-based life science consultancy founded in 1997 that delivers pre-launch, launch, and lifecycle strategy, intelligence, and communications services to biopharmaceutical companies through a curated Network of Excellence model and an AI-powered practice area.
Ownership category
akta.pro rank

PHASE II International industry classification

Industry
Product category
Life Science Consultancy
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAJ
Post-Approval Clinical Development (Phase IV & Lifecycle Management)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Life science consultancy
  • Pharmaceutical market intelligence
  • Biopharmaceutical strategy
  • Medical communications agency
  • Healthcare brand strategy

Where PHASE II International is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

PHASE II International business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Market Intelligence Services: MLA (Market Landscape Analysis), CBA (Competitor Benchmarking Analysis), CPA (Customer Profiling Analysis), MM&F (Market Modelling & Forecasting), CIS (Competitor Intelligence Services), BIR (Bespoke Insight Research), KOL Identification & Influence Mapping
  2. Strategy Development Services: Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, Thought leader advocacy planning, BrandPlan, PatPlan processes delivered through moderated workshops
  3. Communication Programs: Integrated Communications & Commercialization Planning, Project Implementation, Creative Advertising Campaigns (branded and unbranded), Scientific exhibition booth panels, Video production
  4. Agency of Record Engagements: Full array of integrated strategic services encompassing market research, analysis and intelligence services; strategic product and launch planning; and development/implementation of scientific, market access and creative medical communication programs

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Professional Services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

PHASE II International product offering

Product offering

Core offering

PHASE II International is a life science consultancy that helps biopharmaceutical companies plan, launch and lifecycle-manage products by delivering market intelligence, strategic planning and medical communications through a curated Network of Excellence of independent specialists. It bundles these capabilities into ongoing Agency of Record engagements and project-based Ad Hoc Consultancy assignments, with an embedded "PHASE II | AI" practice applying NLP, machine learning predictive analytics for early disease detection, and generative AI tools to its intelligence, strategy and creative workstreams.

Product overview

PHASE II International is a life science consultancy operating since 1997 through a curated 'Network of Excellence' — a virtual organization of independent specialists assembled bespoke for each client engagement. The company offers three integrated core service pillars: Market Intelligence Services (MLA, CBA, CPA, MM&F, CIS, BIR, KOL Identification), Strategy Development (Pre-Strat, TPPO, TCPO, SciPlat, PosStrat, ComStrat, ComPlan, SciPlan, MarPlan, BrandPlan, PatPlan), and Communication Programs (integrated communications and branded/unbranded creative advertising campaigns). These services are delivered across two engagement models — Agency of Record (ongoing strategic support) and Ad Hoc Consultancy (project-specific expertise) — primarily supporting biopharmaceutical companies in pre-launch, launch, and lifecycle phases across hematology, oncology, immunology, and rare disease. A distinct AI-powered practice area branded 'PHASE II | AI' overlays the core services with NLP for market research, machine learning predictive analytics for early disease detection and clinical trial patient matching, and generative AI tools for creative ideation. The company also maintains sister organization Scientific Education Support (SES) for independent accredited medical education, which is operationally firewalled from PHASE II.

Differentiator

Problem solved

Functional benefit

Products and services

  • Market Intelligence Services A suite of market research and intelligence offerings for life science companies encompassing Market Landscape Analysis (MLA), Competitor Benchmarking Analysis (CBA), Customer Profiling Analysis (CPA), Market Modelling & Forecasting (MM&F), Competitor Intelligence Services (CIS), Bespoke Insight Research (BIR), and KOL Identification & Influence Mapping. Designed for Business Intelligence, Medical Affairs and Commercial teams seeking market intelligence, competitor benchmarking and strategic insights to support pre-launch and launch decisions.
  • Strategy Development A portfolio of proprietary strategic planning processes delivered through moderated workshops: Pre-Strat (Pre-Clinical Candidate Selection), TPPO (Target Product Profile Optimization), TCPO (Target Clinical Profile Optimization), SciPlat (Scientific Platform & Core Claims), PosStrat (Product Positioning & Key Messages), ComStrat (Communications Strategy), ComPlan (Communication Planning), SciPlan (Scientific Publication Planning), MarPlan (Market Access Planning), Thought Leader Advocacy Planning, BrandPlan (Brand Communications Planning), and PatPlan (Patient Engagement & Advocacy Planning). For Medical Affairs, Clinical Development, Market Access and Commercial teams planning new product launches and lifecycle phases.
  • Communication Programs Integrated communications and creative advertising campaigns (branded and unbranded) that translate complex scientific and technical information into clear, actionable messaging for healthcare professionals, patients, payers and the general public. Includes scientific exhibition booth panel development, video production and full project implementation. For Commercial and Marketing teams within biopharmaceutical companies.
  • PHASE II | AI AI-powered practice area encompassing Natural Language Processing (NLP) for market research transcription, sentiment analysis (emotion detection) and report generation; machine learning algorithms and AI-powered analytics platforms for predictive analytics, early disease detection (up to five years pre-onset) and matching patients to open/recruiting clinical trials based on eligibility criteria; and generative creative design tools (DALL-E, GPT-3) for medical education and marketing communication ideation.
  • Market Access & HEOR Services Market access strategies, optimized health economics outcomes research programs, and value demonstration communications for biopharmaceutical clients. Encompasses Systematic Literature Reviews (SLRs), Global Value Dossiers (GVDs), HTA submissions and implementation per EU country, and pathways to successful negotiation with local payers across EU countries. For Market Access teams seeking to demonstrate clinical and economic value of products.
  • Strategic Advisory Board Services PHASE II-moderated Expert Advisory Boards covering global regions (US, Europe, Asia Pacific) supporting Phase 2-to-Phase 3 transition planning. Includes facilitation of consensus disease definitions, unmet clinical needs, target patient segmentation, TPP criteria, AI prediction models for disease identification, and inclusion/exclusion criteria for Phase 3 trials.
  • Scientific Exhibition Booth Panel Development Full-service scientific exhibition booth panel development for international congresses (EHA, ASCO, ASH), encompassing research, copywriting, editing, referencing, original graphics creation using BioRender, high-resolution artwork preparation, and logistics management for delivery to congress venues. For biopharmaceutical companies seeking scientific presence at major international hematology and oncology congresses.
  • Corporate Brand Communications Guide Comprehensive corporate brand identity development and documentation services for pharmaceutical and biotechnology companies, including logo usage guidelines, vision line application, typography standards, color palettes, imagery guidelines, advertising templates, presentation templates, scientific poster templates, corporate brochure templates, and style guidelines for devices and icons.
  • Clinical Trial Center Mapping & Profiling Market intelligence service mapping and profiling clinical trial centers of excellence, including hospital type classification, hematology specialty, principal investigator details, patient volumes, Phase 1 facilities, and clinical trial participation status for both sponsor and competitor trials. For Clinical Development and Clinical Operations teams at biopharmaceutical sponsors.

Quantifiable outcome

  • Supported over 30 life science companies and 35 life science brands since 1997
  • +2 more outcomes

Companies that use PHASE II International

Customer profile

Named customers8 records

Segments5 records

Ideal customer profiles2 records

PHASE II International technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

PHASE II International partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Network of Excellence (Associates & Partners)coreStrategic or Co-development Partner · 1 January 1997Since 1997, PHASE II has developed an extensive global Network of Excellence consisting of scientific and clinical thought leaders, discipline experts and associates as well as life science and academic partners. Key named partners include: Stephen Nicholson PhD (Medical Oncologist), Tim Hardman PhD (Senior Medical Strategist), Paul Miller PhD (Independent Health Economist), Melanie Martin MRPharmS (Director, A-Z Medical Writing), Susanne Gulliver BA MPH (Senior Epidemiologist), Felix Chapovsky MD (Medical Strategy Consultant), David Zsaritsky (President of The Agency Network, MJH Lifesciences), and many others across medical, creative, digital, health economics, market research, video production, and AI disciplines.
  • The Agency Network (TAN), part of MJH LifesciencescoreGTM or Marketing PartnerDavid Zsaritsky serves as President of The Agency Network (TAN), part of MJH Lifesciences, acting as US Partner Agency to PHASE II International. This partnership extends PHASE II's reach into the US market.
  • Patient Advocacy Groups & AssociationsminorStrategic or Co-development PartnerPatient networks and associations PHASE II has collaborated with include: ALAN, Cancer Care, FOCiS, and Lymphoma Coalition. These partnerships support patient engagement and advocacy planning services.
  • Medical SocietiesminorStrategic or Co-development PartnerMedical societies PHASE II has collaborated with include ELI, ELN, ESH, and FoCiS. These partnerships support scientific engagement and thought leader activities.
  • Scientific Education Support (SES)minorStrategic or Co-development PartnerSES is PHASE II's sister organization specializing in independent and accredited medical education programs. Operations are completely firewalled from PHASE II. SES and PHASE II are separate legal entities.
  • Niche Science & Technology LtdminorStrategic or Co-development PartnerTim Hardman PhD, Managing Director of Niche Science & Technology Ltd, serves as Senior Scientific Strategist and Medical Writer. Represents strategic partnership for scientific writing capabilities.
  • NewLab Clinical ResearchminorStrategic or Co-development PartnerSusanne Gulliver BA MPH, Senior Epidemiologist, Research & Operations and CEO of NewLab Clinical Research. Represents strategic partnership for epidemiological research capabilities.
  • Miller Economics LtdminorStrategic or Co-development PartnerPaul Miller BA, MSc, PhD, Director at Miller Economics Ltd, serves as Value Demonstration/Health Economics Lead. Represents strategic partnership for health economics capabilities.
  • Lessis MooreminorStrategic or Co-development PartnerMaria Szmit, Director at Lessis Moore, provides Senior Graphic Design & UX capabilities. Represents strategic partnership for design services.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

PHASE II International competitors and assessment

Company assessment

Direct peers

  • The Lockwood Group: Healthcare communications and consulting agency serving pharma and biotech with strategic planning and creative services. Comparable on launch strategy, KOL engagement and content development for life science clients.
  • Trinity Life Sciences: Strategic consulting firm providing commercial strategy, market intelligence, and launch planning to biopharma clients. Directly comparable to PHASE II on the Strategy Development and Market Intelligence pillars of the offering.
  • Healthcare Consultancy Group (HCG): Strategic consultancy supporting pharma and biotech with medical affairs, market access and patient engagement consulting. Comparable to PHASE II's strategic advisory and HEOR-related service lines.
  • ApotheCom (Ashfield Health): Medical communications agency offering scientific engagement, publications planning and strategic services to biopharma. Directly comparable across PHASE II's medical affairs, publications and stakeholder engagement services.
  • Fishawack Health (Inizio): Specialist medical communications and consulting group with global delivery across commercial, medical and patient engagement functions. Competes head-to-head on lifecycle and launch services for life science brands.
  • Caudex (IPG Health): Medical communications and consulting agency serving pharma and biotech across launch and lifecycle. Closely aligned to PHASE II's medical affairs, market access and brand communications workstreams.
  • Chameleon Communications (Inizio): Boutique medical communications agency focused on scientific storytelling and engagement for pharma clients. Overlaps with PHASE II's branded and unbranded creative, congress and advisory board support.

Broad incumbents

  • Real Chemistry: Healthcare-focused marketing, communications and data analytics firm offering integrated commercial services to life science clients. Wider portfolio with data and technology capabilities beyond PHASE II's specialist footprint.
  • IQVIA: Global life science services company providing commercial and clinical solutions including market intelligence, launch support and consulting. Competes on the data depth and global delivery scale that PHASE II lacks.

Emerging players

  • Dudnyk (Inizio): Health communications agency with strong focus on rare disease and specialty therapeutics. Directly overlaps with PHASE II's rare disease launch work such as the Pharvaris HAE franchise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

PHASE II International social profiles

Digital presence

PHASE II International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PHASE II International leadership team

Management profile

Number of profiles

Profiles2 records

PHASE II International funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PHASE II International M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PHASE II International

What does PHASE II International do?

PHASE II International is a life science consultancy that helps biopharmaceutical companies plan, launch and lifecycle-manage products by delivering market intelligence, strategic planning and medical communications through a curated Network of Excellence of independent specialists. It bundles these capabilities into ongoing Agency of Record engagements and project-based Ad Hoc Consultancy assignments, with an embedded "PHASE II | AI" practice applying NLP, machine learning predictive analytics for early disease detection, and generative AI tools to its intelligence, strategy and creative workstreams.

Is PHASE II International a public or private company?

PHASE II International is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was PHASE II International founded?

PHASE II International was founded in 1997. It employs 11 to 50 people.

Where is PHASE II International based?

PHASE II International is headquartered in London, United Kingdom, in the Europe region.

How does PHASE II International make money?

Four revenue lines are on record. Market Intelligence Services are the primary driver. The others are strategy Development Services, communication Programs and agency of Record Engagements.

Who are PHASE II International's main competitors?

Direct peers on record are The Lockwood Group, Trinity Life Sciences, Healthcare Consultancy Group (HCG), ApotheCom (Ashfield Health), Fishawack Health (Inizio), Caudex (IPG Health) and Chameleon Communications (Inizio). Broad incumbents are Real Chemistry and IQVIA. Dudnyk (Inizio) is listed as an emerging player.

Does PHASE II International have an API?

No public API is recorded for PHASE II International.

What industry is PHASE II International in?

PHASE II International's product category is Life Science Consultancy. Its primary akta.pro industry code is HLAIALAJ, Post-Approval Clinical Development (Phase IV & Lifecycle Management), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales